Whalegun
Home

Halozyme Therapeutics HALO paid Forbes-Tate $60K for lobbying in Q3 2024 · Health Issues

Trade details

Type
Lobbying report
Amount
$60,000
Quarter
Q3 2024
Stock
Halozyme Therapeutics HALO
Client
Halozyme Therapeutics
Reported
24/10/17

Up 0.0% from last quarter

What else happened in Halozyme Therapeutics around then

Filed or reported within 30 days of the trade day · 24/08/31~24/10/30

Halozyme Therapeutics's other lobbying reports

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $80K

    Reported 07/20

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $70K

    Reported 04/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 01/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 25/10/18

  • Halozyme Therapeutics

    LobbyingHalozyme Therapeutics

    $60K

    Reported 25/07/18

Halozyme Therapeutics HALO paid Forbes-Tate $60K for lobbying in Q3 2024 · Health Issues | Whalegun